Jianfeng Group Lin2016 -006 (Announcement of 906 Board Resolution)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2016-006
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
九届六次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2016年3月28日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2016年4月8日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事8人,实际出席会议的董事8人,会议有效表决票数8票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2015年度总经理业务报告
经审议,董事会一致通过了该报告。
表决结果:同意8票、反对0票、弃权0票。
2、通过了2015年度财务决算报告
董事会审议并通过了该报告,本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
3、通过了2015年度利润分配议案
经天健会计师事务所审计,2015年度公司合并报表归属于母公司股东的净利润为200,899,362.77 元;母公司会计报表净利润140,843,091.13元。按母公司的本期净利润140,843,091.13元为基数,提取10%法定公积金14,084,309.11元,加年初未分配利润407,611,924.40元,减去2014年度现金分红86,020,957.00元,本年度可供分配利润为448,349,749.42元。
公司2015年度拟进行现金分配,以2015年末股本344,083,828股为基数,每10股派发现金红利1.80元(含税),向股权登记日登记在册的全体股东派发现金股利总额为61,935,089.04元(含税)。
2015年度不进行公积金转增股本。
该预案将提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
4、通过了聘请公司2016年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所为公司2016年度财务及内部控制审计机构。本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
5、通过了2015年年度报告及其摘要
董事会审议并通过了该报告,本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
2015年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
董事会一致通过了该议案,同意为控股子公司提供以下担保事宜。
(1)对控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
10000 |
|
浙江尖峰药业有限公司 |
30000 |
|
金华市医药公司 |
15000 |
|
浙江尖峰国际贸易有限公司 |
5000 |
|
云南尖峰水泥有限公司 |
5000 |
|
合计 |
65000 |
(2)同意为浙江尖峰国际贸易有限公司提供担保函,为浙江尖峰国际贸易有限公司的客户在该公司存放的货物提供相应的担保。
在以上额度内的担保授权董事长分次执行。
本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
详见《对控股子公司提供担保的公告》(临2016-008)。
7、通过了与浙江凯恩特种材料股份有限公司互相担保的议案
董事会审议并通过了该议案,同意与浙江凯恩特种材料股份有限公司进行额度为5000万元、期限为一年的等额互保。
本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
详见《与浙江凯恩特种材料股份有限公司互相担保的公告》(临2016-009)。
8、通过了2015年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
9、通过了关于修改内控手册的议案
董事会审议并通过了该议案,同意对内控手册中的部分制度进行修订。
表决结果:同意8票、反对0票、弃权0票。
本次修订的内控手册中的《尖峰集团筹资管理制度》和《尖峰集团对外投资管理制度》详见上海证券交易所网站(http://www.sse.com.cn)。
10、通过了2015年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,提取2015年度中长期激励基金为6213382.35元。
表决结果:同意8票、反对0票、弃权0票。
11、通过了关于增补独立董事的议案
董事会审议并通过了该议案。公司董事会同意提名孙宏斌先生为本公司独立董事候选人,提交股东大会选举。简历见附件。
表决结果:同意8票、反对0票、弃权0票。
12、通过了关于对天士力集团增资的关联交易议案
董事会审议并通过了该议案。关联董事蒋晓萌先生、杜自弘先生回避了该项议案的表决。
表决结果:同意6票、反对0票、弃权0票。
该报告将提交股东大会审议。
详见《关于对天士力集团增资的关联交易公告》(临2016-010)。
13、通过了关于对尖峰药业增资的关联交易议案
董事会审议并通过了该报告。关联董事蒋晓萌先生回避了该项议案的表决。
表决结果:同意7票、反对0票、弃权0票。
详见《关于对尖峰药业增资的关联交易公告》(临2016-011)。
公司独立董事事前对第12、13两个事项进行了审议,认为:上述两项关联交易的增资价格依据经审计的净资产决定,且按各股东持股比例享有增资权,公司参与增资后能确保不降低所占的股权份额。上述关联交易实施后将有效优化被投资公司的资产结构,增强企业实力、提升竞争力,确保企业持续健康发展。以上关联交易没有损害公司及股东的利益,同意将该议案提交给公司第九届董事会第6次会议审议。
董事会审计委员会对第12、13两个事项发表了审核意见:认为上述关联交易属于公司正常的经济行为,符合公司经营发展需要;增资的价格都依据经审计的净资产决定,且按各股东持股比例享有增资权,增资后本公司所占被投资单位的股权份额不会下降;交易遵循了公平、公正、自愿、诚信的原则,没有损害公司及股东的利益,予以同意。
14、通过了关于召开2015年度股东大会的议案
董事会决定于2016年5月9日在浙江省金华市婺江东路88号尖峰大厦召开2015年度股东大会。
表决结果:同意8票、反对0票、弃权0票
详见《关于召开2015年度股东大会的通知》(临2016-012)。
15、通过了2015年度独立董事述职报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票
独立董事将向股东大会报告。
16、通过了董事会审计委员会2015年度履职报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票
17、通过了2015年度董事会工作报告
表决结果:同意8票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述3、4、6、7、10、11、12、13八项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第九届独立董事对上述相关事项的独立董事意见,对关联交易事项的事前认可声明;审计委员会对关联交易事项的书面审核意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年四月十二日
附件:
孙宏斌先生,1966年12月出生,理学博士、教育部“长江学者”特聘教授。先后在中科院上海有机化学研究所、德国亚琛工业大学和美国佛罗里达大学从事博士后研究工作,在美国加州Metabolex公司从事新药研究工作。现任中国药科大学教授、博士生导师、新药研究中心主任,兼任江苏省代谢性疾病药物重点实验室主任、“天然药物活性组分与药效”国家重点实验室副主任、中国药学会药物化学专业委员会委员、江苏省药学会药物化学专业委员会副主任委员、中国药科大学学位评定委员会和学术委员会委员、国家基金委医学部“十三五”发展战略研究“药物学”专家组副组长、国家技术发明奖会议评审专家、江苏威凯尔医药科技有限公司名誉董事长等职。
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11